Colon AdenomaNCT03919487
Surrogate Quality Indicators for Adenoma Detection Rate (ADR)
An observational study of Colon Adenoma, run by Soonchunhyang University Hospital at 1 site in South Korea.
Trial summary
This study is to evaluate the correlation of adenoma missing rate and quality indicators of colonoscopy including adenoma detection ratee (ADR), polyp detection rate (PDR), adenoma per colonoscopy rate (APC), adenoma per positive participant (APP), ADR-Plus, and to find out the surrogate indicators of ADR. Read more about this study
- Who is it for?
- Ages 50 to 75 yearsHealthy volunteers can take part
- Conditions the study is for
- Colon Adenoma
- What is being tested?
- Back to back colonoscopy
- Type of treatment
- Surgery or procedure
- How many people
- 400 participants
- Where
- 1 siteSouth Korea
- Study dates
- 1 Jul 2018to 18 Dec 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 75 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Community based, screening colonoscopy subjects
Who may be able to join
- A 50-to 75-year-old colon cancer screening colonoscopist who has had previous colonoscopy experience or has had a colonoscopy within the last 5 years
Who cannot join
- Total bowel preparation deficient (total bowel preparation by Boston bowel preparation scale <6 or any region score <2)
- Inflammatory bowel disease patients
- Family history of hereditary colorectal cancer (family history of two or more colorectal cancer or family history of at least one cancer diagnosed before age 60)
- History of colorectal cancer or colon surgery
- If the insertion of the appendix fails
- A patient who does not agree with sleep induction calming
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Correlation Between Surrogate Quality Indicators for Adenoma Detection Rate (ADR) and Adenoma Miss Rate (AMR) in Qualified Colonoscopy: CORE Study
This study is to evaluate the correlation of adenoma missing rate and quality indicators of colonoscopy including adenoma detection ratee (ADR), polyp detection rate (PDR), adenoma per colonoscopy rate (APC), adenoma per positive participant (APP), ADR-Plus, and to find out the surrogate indicators of ADR. This study is a prospective observational multi-center study. Correlation between AMR and quality indicators of colonoscopy based on the previous studies, 8 endoscopists participated in this study and will enroll 50 screening colonoscopies respectively.
Recruit research participants who want to participate in research in outpatient clinics. Perform colonoscopy in the morning after colon cleansing with split method. Colonoscopy is performed by back-to-back two consecutive colonoscopies. When the first colonoscopy is performed, the colonoscope is retracted after inserting the cecum, and all colon polyps are removed. After retracting to the anus of the first colonoscopy, the second colonoscopy is performed immediately. In case of newly detected colon polyps except for the small polyps and S-colon and rectal polyps which were left as photographs during the first colonoscopy with the second colonoscopy, we regard them as an overlooked lesion during the first colonoscopy. After the procedure, the histologic examination is confirmed and classified as benign lesions (all adenomas, advanced adenomas, dysplasia, and colorectal cancer) and non-lesion lesions.
Using the back-to-back colonoscopy results of the participants during the study period, calculate the quality indicators including ADR, PDR, APC, ADR-plus, APP and AMR for each endoscopist. And then, evaluate the correlation between AMR and other quality indicators.
Read the detailed description
Background Colonoscopy reduces the risk of colorectal cancer by 77% and reduces mortality from colorectal cancer by more than 30%. However, in spite of the advantages of colonoscopy, the meta-analysis reported an incidence of intermediate cancer of 3.7%. In the case of proximal colon, the incidence of intermediate cancer was 2.4 times higher than that of the distal colon.
There are several possible causes of intermediate cancers, such as missed lesion during the previous colonoscopy, early-growth tumors before the follow-up period, and incomplete resection of the lesions. About 70-80% intermediate cancers are known to be originated from an missed lesion on endoscopy, and 10 ~ 27% is known to be caused by incomplete resection of the lesion on the previous colonoscopy.
The quality of colonoscopy for the prevention of intermediate cancer was first reported by the American Society of Gastrointestinal Endoscopy (ASGE) / American College of Gastroenterology (ACG) Task Force on Quality in Endoscopy in 2006 and the recently revised Quality indicators for colonoscopy (Quality index of colonoscopy) '.
The most popular and practically being used quality indicator of colonoscopy is an adenoma detection rate (ADR).
ADR is calculated as the number of colonoscopy with ≥1 adenoma detected during the colonoscopy divided by the total number of colonoscopies. ACGTF recommended the criteria of the quality index of the colonoscopy prior to the revision ADR was defined as 25% or more for men and 15% or more for women.
However, a Polish study reported a 10-fold higher risk of intermediate cancer when ADR was below 20%, and a recent large study by Corley showed that the incidence of colorectal cancer could be reduced by 3% and the mortality rate of colorectal cancer by 5% or more, especially when the ADR is increased by 1%.
Based on the evidence that the higher the ADR and the lower the risk of colorectal cancer, the quality index of colonoscopy was revised in 2015. Currently, the recommended ADR is 30% for men and 20% for women.
Although ADR appears to be a perfect quality marker, it requires a diagnosis of adenoma of the pathologic outcome in order to obtain ADR.
In particular, the calculation of ADR is based on the assumption that more than one adenoma is diagnosed during colonoscopy. However, even if the number of adenomas diagnosed during colonoscopy is different for each endoscopist, the concept of ADR does not distinguish this difference.
In fact, many recent studies have reported that endoscopist with an ADR more than 40% showed more than 20% adenoma missing rate.
The recent proposed measures to replace ADR include polyp detection rate (PDR) and adenoma per colonoscopy rate (APC). As with ADR, PDR is a measure of the rate at which more than one colorectal polyps are found in a colonoscopy practitioner aged 50 years or older. Unlike ADR, PDR does not need pathologic result. Recently, several studies have been reported that PDR can replace ADR and can be correlated with colorectal cancer prevention. The APC is different from that of ADR, and it is considered to be one of the alternative indicators that can compensate the shortcomings of "one and done" concept of ADR, because it can reflect the number of all adenomas found in the entire colon. According to a single-institution study using more than 20,000 colonoscopy analyzes that the recommended values for ADR 20% for men and women with ADR 15% for men over 50 years of age were APC 0.3.
In addition to APC, Adenoma per positive participants (APP), the total number of adenomas of participants divided by the number of examinees of adenomas detected (positive APPs), and the number of ADR-plus (ADR-plus) in the average number of additional found adenomas per test case divided by total colonoscopy were also introduced as quality indicators to predict the overlook of the lesion substitute for ADR.
In this regard, various substitute factors such as PDR, APC, and recently reported APP and ADR-plus have been introduced as an index parameter that can be used as a quality index to reflect the neglect of adenomas during colonoscopy. However, there is a very limited study of the direct comparison of correlation between each quality indicators and adenoma miss rate (AMR), and also the investigators have very limited knowledge which quaility incidator can well reflect the AMR.
The aim of this study was to investigate the efficacy of quality indicators which could best reflect the AMR and to find surrogate markers of ADR.
The primary endpoint of this study is to evaluate the relationship between known quality markers such as ADR, PDR, APC, APP, ADR-Plus, and AMR is examined.
This study will be performed as a cross-sectional study with prospective design.
Total of eight expert colonoscopists will participate in this study, and collecting the 50 colonoscopy data in each endoscopist. All enrolled cases will be subject for screening colonoscopy aged 50-75 years old.
This study excluded the colonoscopy cases with inappropriate bowel preparation, inflammatory bowel disease patients, and high-risk patients with family history of hereditary colorectal cancer.
Colon cleansing will be performed by the split method. Colonoscopy is performed by back-to-back two colonoscopies. When the first colonoscopy is performed, the colonoscope is retracted after inserting the cecum, and all colon polyps are removed. Only small polyps less than 5 mm located in the S-colon and rectum are left after photographing.
After performing the first colonoscopy, the second colonoscopy is performed immediately. A newly founded polyp (except polypoid and S-colon and rectal polyp which was left as a photograph at the time of 1st colonoscopy when performing a second colonoscopy) will be considered as a missed lesion and will be removed. After the procedure, confirm the presence of adenomatous polyps by pathologic results and record them on the case record. Using the back-to-back colonoscopy results of the participants during the study period, calculate the quality indicators including ADR, PDR, APC, ADR-plus, APP, and AMR. The correlations between ADR, PDR, APC, ADR-plus, APP, and AMR are compared using Pearson correlation constants.
- Conditions
- Colon Adenoma
- Being tested
- Back to back colonoscopy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Back to back colonoscopyProcedure or surgery
Also called colonoscopy
After first colonoscopy performing with polypectomy, the 2nd colonoscopy will be performed right after the 1st colonoscopy, and if the missed lesion during the 1st colonoscopy will be found, it should be removed.
| Study group | Role | What they receive |
|---|---|---|
| Back-to-back colonoscopy group | As I described the study method in the protocol, the experimental group will be a screening colonoscopy cohort with back to back method. In fact, this study is to evaluate the correlation between quality indicators of colonoscopy and adenoma miss rate (AMR), and intervention is a single arm for back-to-back colonoscopy. Receives: Procedure: Back to back colonoscopy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Correlation between adenoma missing rate during the colonoscopy and other colonoscopy quality indicators in each endoscopist.
colonoscopy quality indicators including adenoma detection rate, polyp detection rate, adenoma per colonoscopy, adenoma detection rate-plus, adenoma per positive participant
Measured: Within 1 year
Secondary outcomes (1)
Evaluation of surrogate indicators of ADR
Correlation between ADR and other substitute indicators including PDR, APC, ADR-P
Measured: Within 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Apr 2019
- Study start1 Jul 2018
- Primary completion30 Jun 2020
- Study completion18 Dec 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Colon AdenomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 400 participants (actual)
Sponsor and investigators
- Lead sponsor
- Soonchunhyang University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Hyun Gun, Kim. M.D., Ph.D., Soonchunhyang University Hospital
- Investigators
- Hyun Gun Kim, Professor, Study director, Soonchunhyang University College of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03919487
- Sponsor's protocol ID
- CORE study
- Status last verified
- Mar 2021
- First submitted
- 7 Mar 2019
- Last updated
- 10 Mar 2021
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Mar 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Correlation Between Surrogate Quality Indicators for Adenoma Detection Rate (ADR) and Adenoma Miss Rate (AMR) in Qualified Colonoscopy: CORE Study
- ClinicalTrials.gov ID
- NCT03919487
- Acronym / sponsor ID
- CORE study
- Conditions
- Colon Adenoma
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 400 participants (actual)
- Lead sponsor
- Soonchunhyang University HospitalUniversity, hospital or other
- Study start
- 1 Jul 2018 (actual)
- Primary completion
- 30 Jun 2020 (actual)
- Study completion
- 18 Dec 2020 (actual)
- First posted
- 18 Apr 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is to evaluate the correlation of adenoma missing rate and quality indicators of colonoscopy including adenoma detection ratee (ADR), polyp detection rate (PDR), adenoma per colonoscopy rate (APC), adenoma per positive participant (APP), ADR-Plus, and to find out the surrogate indicators of ADR. This study is a prospective observational multi-center study. Correlation between AMR and quality indicators of colonoscopy based on the previous studies, 8 endoscopists participated in this study and will enroll 50 screening colonoscopies respectively.
Recruit research participants who want to participate in research in outpatient clinics. Perform colonoscopy in the morning after colon cleansing with split method. Colonoscopy is performed by back-to-back two consecutive colonoscopies. When the first colonoscopy is performed, the colonoscope is retracted after inserting the cecum, and all colon polyps are removed. After retracting to the anus of the first colonoscopy, the second colonoscopy is performed immediately. In case of newly detected colon polyps except for the small polyps and S-colon and rectal polyps which were left as photographs during the first colonoscopy with the second colonoscopy, we regard them as an overlooked lesion during the first colonoscopy. After the procedure, the histologic examination is confirmed and classified as benign lesions (all adenomas, advanced adenomas, dysplasia, and colorectal cancer) and non-lesion lesions.
Using the back-to-back colonoscopy results of the participants during the study period, calculate the quality indicators including ADR, PDR, APC, ADR-plus, APP and AMR for each endoscopist. And then, evaluate the correlation between AMR and other quality indicators.
Detailed description
Background Colonoscopy reduces the risk of colorectal cancer by 77% and reduces mortality from colorectal cancer by more than 30%. However, in spite of the advantages of colonoscopy, the meta-analysis reported an incidence of intermediate cancer of 3.7%. In the case of proximal colon, the incidence of intermediate cancer was 2.4 times higher than that of the distal colon.
There are several possible causes of intermediate cancers, such as missed lesion during the previous colonoscopy, early-growth tumors before the follow-up period, and incomplete resection of the lesions. About 70-80% intermediate cancers are known to be originated from an missed lesion on endoscopy, and 10 ~ 27% is known to be caused by incomplete resection of the lesion on the previous colonoscopy.
The quality of colonoscopy for the prevention of intermediate cancer was first reported by the American Society of Gastrointestinal Endoscopy (ASGE) / American College of Gastroenterology (ACG) Task Force on Quality in Endoscopy in 2006 and the recently revised Quality indicators for colonoscopy (Quality index of colonoscopy) '.
The most popular and practically being used quality indicator of colonoscopy is an adenoma detection rate (ADR).
ADR is calculated as the number of colonoscopy with ≥1 adenoma detected during the colonoscopy divided by the total number of colonoscopies. ACGTF recommended the criteria of the quality index of the colonoscopy prior to the revision ADR was defined as 25% or more for men and 15% or more for women.
However, a Polish study reported a 10-fold higher risk of intermediate cancer when ADR was below 20%, and a recent large study by Corley showed that the incidence of colorectal cancer could be reduced by 3% and the mortality rate of colorectal cancer by 5% or more, especially when the ADR is increased by 1%.
Based on the evidence that the higher the ADR and the lower the risk of colorectal cancer, the quality index of colonoscopy was revised in 2015. Currently, the recommended ADR is 30% for men and 20% for women.
Although ADR appears to be a perfect quality marker, it requires a diagnosis of adenoma of the pathologic outcome in order to obtain ADR.
In particular, the calculation of ADR is based on the assumption that more than one adenoma is diagnosed during colonoscopy. However, even if the number of adenomas diagnosed during colonoscopy is different for each endoscopist, the concept of ADR does not distinguish this difference.
In fact, many recent studies have reported that endoscopist with an ADR more than 40% showed more than 20% adenoma missing rate.
The recent proposed measures to replace ADR include polyp detection rate (PDR) and adenoma per colonoscopy rate (APC). As with ADR, PDR is a measure of the rate at which more than one colorectal polyps are found in a colonoscopy practitioner aged 50 years or older. Unlike ADR, PDR does not need pathologic result. Recently, several studies have been reported that PDR can replace ADR and can be correlated with colorectal cancer prevention. The APC is different from that of ADR, and it is considered to be one of the alternative indicators that can compensate the shortcomings of "one and done" concept of ADR, because it can reflect the number of all adenomas found in the entire colon. According to a single-institution study using more than 20,000 colonoscopy analyzes that the recommended values for ADR 20% for men and women with ADR 15% for men over 50 years of age were APC 0.3.
In addition to APC, Adenoma per positive participants (APP), the total number of adenomas of participants divided by the number of examinees of adenomas detected (positive APPs), and the number of ADR-plus (ADR-plus) in the average number of additional found adenomas per test case divided by total colonoscopy were also introduced as quality indicators to predict the overlook of the lesion substitute for ADR.
In this regard, various substitute factors such as PDR, APC, and recently reported APP and ADR-plus have been introduced as an index parameter that can be used as a quality index to reflect the neglect of adenomas during colonoscopy. However, there is a very limited study of the direct comparison of correlation between each quality indicators and adenoma miss rate (AMR), and also the investigators have very limited knowledge which quaility incidator can well reflect the AMR.
The aim of this study was to investigate the efficacy of quality indicators which could best reflect the AMR and to find surrogate markers of ADR.
The primary endpoint of this study is to evaluate the relationship between known quality markers such as ADR, PDR, APC, APP, ADR-Plus, and AMR is examined.
This study will be performed as a cross-sectional study with prospective design.
Total of eight expert colonoscopists will participate in this study, and collecting the 50 colonoscopy data in each endoscopist. All enrolled cases will be subject for screening colonoscopy aged 50-75 years old.
This study excluded the colonoscopy cases with inappropriate bowel preparation, inflammatory bowel disease patients, and high-risk patients with family history of hereditary colorectal cancer.
Colon cleansing will be performed by the split method. Colonoscopy is performed by back-to-back two colonoscopies. When the first colonoscopy is performed, the colonoscope is retracted after inserting the cecum, and all colon polyps are removed. Only small polyps less than 5 mm located in the S-colon and rectum are left after photographing.
After performing the first colonoscopy, the second colonoscopy is performed immediately. A newly founded polyp (except polypoid and S-colon and rectal polyp which was left as a photograph at the time of 1st colonoscopy when performing a second colonoscopy) will be considered as a missed lesion and will be removed. After the procedure, confirm the presence of adenomatous polyps by pathologic results and record them on the case record. Using the back-to-back colonoscopy results of the participants during the study period, calculate the quality indicators including ADR, PDR, APC, ADR-plus, APP, and AMR. The correlations between ADR, PDR, APC, ADR-plus, APP, and AMR are compared using Pearson correlation constants.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Back-to-back colonoscopy group | – | Procedure: Back to back colonoscopyAs I described the study method in the protocol, the experimental group will be a screening colonoscopy cohort with back to back method. In fact, this study is to evaluate the correlation between quality indicators of colonoscopy and adenoma miss rate (AMR), and intervention is a single arm for back-to-back colonoscopy. |
Who may qualify
- Ages
- 50 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Community based, screening colonoscopy subjects
Key inclusion criteria (1 listed)
- A 50-to 75-year-old colon cancer screening colonoscopist who has had previous colonoscopy experience or has had a colonoscopy within the last 5 years
Key exclusion criteria (6 listed)
- Total bowel preparation deficient (total bowel preparation by Boston bowel preparation scale <6 or any region score <2)
- Inflammatory bowel disease patients
- Family history of hereditary colorectal cancer (family history of two or more colorectal cancer or family history of at least one cancer diagnosed before age 60)
- History of colorectal cancer or colon surgery
- If the insertion of the appendix fails
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Back to back colonoscopyAlso: colonoscopyAfter first colonoscopy performing with polypectomy, the 2nd colonoscopy will be performed right after the 1st colonoscopy, and if the missed lesion during the 1st colonoscopy will be found, it should be removed. | Procedure or surgery | Back-to-back colonoscopy group |
Primary outcome
Correlation between adenoma missing rate during the colonoscopy and other colonoscopy quality indicators in each endoscopist.
Time frame: Within 1 year
colonoscopy quality indicators including adenoma detection rate, polyp detection rate, adenoma per colonoscopy, adenoma detection rate-plus, adenoma per positive participant
1 secondary outcome
Evaluation of surrogate indicators of ADR
Time frame: Within 1 year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Mar 2021.
Related trials for Colon Adenoma
Active, not recruitingPhase 1/2
A Beta-only IL-2 ImmunoTherapY Study
Advanced Solid Tumor, Unresectable Solid Tumor
RecruitingPhase 1/2
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Pancreatic Ductal Adenocarcinoma, Gastric Cancer
RecruitingObservational study
KLF4 Epigenetic Modulation
KLF4 Methylation, Epigenetic
RecruitingObservational study
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Solid Tumor, Adult, Colorectal Cancer
Active, not recruitingPhase 3
S0820, Adenoma and Second Primary Prevention Trial
Colorectal Neoplasms
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Hyun Gun Kim, Professor study director
Soonchunhyang University College of Medicine
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Colon Adenoma, run by Soonchunhyang University Hospital at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Mar 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Correlation between adenoma missing rate during the colonoscopy and other colonoscopy quality indicators in each endoscopist. (time frame: Within 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Mar 2021.